AL-4943A ophthalmic solution

DRUG3 trials

Sponsors

Alcon Research

Conditions

Allergic Conjunctivitis

Phase 3

Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model

CompletedNCT01479374

Alcon ResearchAllergic Conjunctivitis

Start: 2012-01-31End: 2012-03-31Updated: 2013-06-04

A Six-Week Safety Study of an Investigational Ophthalmic Solution

CompletedNCT01698814

Alcon ResearchAllergic Conjunctivitis

Start: 2012-10-31End: 2013-01-31Updated: 2014-03-27

Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

CompletedNCT01743027

Alcon ResearchAllergic Conjunctivitis

Start: 2013-01-31End: 2013-07-31Updated: 2014-08-11

Related Papers

Treating Allergic Conjunctivitis: A Once-daily Medication that Provides 24-hour Symptom Relief

Allergy & Rhinology2016-01-0119 citations

Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model

Cornea2015-08-1219 citations